Search bioRxiv⌕ Search

Biology subjects

Le Cornu, J. D.

Publications and source records attributed to Le Cornu, J. D..

2 recordsLinked to original sources

S. pombe Mto1:Mto2 stabilizes γ-tubulin positions within the γ-TuRC

Microtubules are present in all eukaryotes and are nucleated by multiprotein {gamma}-tubulin ring complexes ({gamma}-TuRCs), ring-shaped structures that contain several copies of the {gamma}-tubulin small complex ({gamma}-TuSC). {gamma}-TuRCs nucleate microtubules via a template-based mechanism in which the positions of {gamma}-tubulins in the {gamma}-TuSCs match the position of {gamma}-tubulin dimers in the microtubule lattice. Although {gamma}-TuSC proteins are highly conserved, other components of the {gamma}-TuRC can vary in different organisms, as can their relative importance. Here, we characterize two different simplified {gamma}-TuRCs from fission yeast Schizosaccharomyces pombe, using recombinant purified proteins and negative stain electron microscopy. We show that a nucleation-incompetent {gamma}-TuRC that contains only {gamma}-TuSC proteins plus the microprotein Mzt1 ({gamma}-TuSC:Mzt1) can form rings as efficiently as a large, nucleation-competent complex (MGM) that additionally contains the proteins Mto1 and Mto2. We find that the position of {gamma}-tubulins in {gamma}-TuSC:Mzt1 are less well defined than in MGM. Comparative modelling using our electron microscopy and crosslinking mass spectrometry data, together with structures of {gamma}-TuRCs from other organisms, suggests that Mto1 and Mto2 form a multimeric outer mantle surrounding the {gamma}-TuSC:Mzt1 {gamma}-TuRC. This mantle may stabilize positions of {gamma}-tubulins within MGM, explaining the microtubule-nucleating ability of MGM and highlighting the diversity of non-{gamma}-TuSC proteins in modulating {gamma}-TuRC structure and function.

biochemistry↗

A quinolin-8-ol sub-millimolar inhibitor of UGGT, the ER glycoprotein folding quality control checkpoint

The Endoplasmic Reticulum (ER) glycoprotein folding Quality Control (ERQC) machinery aids folding of glycoproteins in the ER. Misfolded glycoprotein recognition and ER-retention is mediated by the ERQC checkpoint enzyme, the 170 kDa UDP-Glucose glycoprotein glucosyltransferase (UGGT). UGGT modulation is a promising strategy for broad-spectrum antivirals, rescue-of-secretion therapy in rare disease caused by responsive mutations in glycoprotein genes, and many cancers, but to date no selective UGGT inhibitors are known. Towards the generation of selective UGGT inhibitors, we determined the crystal structures of the catalytic domain of Chaetomium thermophilum UGGT (CtUGGTGT24), alone and in complex with the inhibitor UDP-2-deoxy-2-fluoro-D-glucose (U2F). Using the CtUGGTGT24 crystals, we carried out a fragment-based lead discovery screen via X-ray crystallography and discovered that the small molecule 5-[(morpholin-4-yl)methyl]quinolin-8-ol (5M-8OH-Q) binds a CtUGGTGT24 WY conserved surface motif that is not present in other GT24 family glycosyltransferases. The 5M-8OH-Q molecule has a 613 {micro}M binding affinity for human UGGT1in vitro as measured by saturation transfer difference NMR spectroscopy. The 5M-8OH-Q molecule inhibits both human UGGT1and UGGT2 activity at concentrations higher than 750 {micro}M in modified HEK293-6E cells. The compound is toxic in cellula and in planta at concentrations higher than 1 mM. A few off-target effects are also observed upon 5M-8OH-Q treatment. Based on an in silico model of the interaction between UGGT and its substrate N -glycan, the 5M-8OH-Q molecule likely works as a competitive inhibitor, binding to the site of recognition of the first GlcNAc residue of the substrate N -glycan. Significance StatementWhen a candidate drug target is the product of a housekeeping gene - i.e. it is important for the normal functioning of the healthy cell - availability of inhibitors for tests and assays is of paramount importance. One such housekeeping protein is UGGT, the enzyme that makes sure that only correctly folded glycoproteins can leave the endoplasmic reticulum for further trafficking through the secretory pathway. UGGT is a potential drug target against viruses, in certain instances of congenital rare disease, and against some cancers, but no UGGT inhibitors are known yet. We discovered and describe here a small molecule that binds human UGGT1 in vitro and inhibits both isoforms of human UGGT in cellula. The compound paves the way to testing of UGGT inhibition as a potential pharmacological strategy in a number of medical contexts.

biochemistry↗